WO2023160035A1 - β-榄香烯乙烯基化偶联衍生物及其制备和在制备抗肿瘤药物中的应用 - Google Patents

β-榄香烯乙烯基化偶联衍生物及其制备和在制备抗肿瘤药物中的应用 Download PDF

Info

Publication number
WO2023160035A1
WO2023160035A1 PCT/CN2022/132420 CN2022132420W WO2023160035A1 WO 2023160035 A1 WO2023160035 A1 WO 2023160035A1 CN 2022132420 W CN2022132420 W CN 2022132420W WO 2023160035 A1 WO2023160035 A1 WO 2023160035A1
Authority
WO
WIPO (PCT)
Prior art keywords
elemene
vinylated
derivatives
pharmaceutically acceptable
derivative
Prior art date
Application number
PCT/CN2022/132420
Other languages
English (en)
French (fr)
Inventor
谢恬
叶杨
徐冰
叶向阳
Original Assignee
杭州师范大学
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 杭州师范大学 filed Critical 杭州师范大学
Priority to EP22924566.7A priority Critical patent/EP4276087A1/en
Priority to JP2023550584A priority patent/JP2024510390A/ja
Publication of WO2023160035A1 publication Critical patent/WO2023160035A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C13/00—Cyclic hydrocarbons containing rings other than, or in addition to, six-membered aromatic rings
    • C07C13/28—Polycyclic hydrocarbons or acyclic hydrocarbon derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B37/00—Reactions without formation or introduction of functional groups containing hetero atoms, involving either the formation of a carbon-to-carbon bond between two carbon atoms not directly linked already or the disconnection of two directly linked carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B37/00—Reactions without formation or introduction of functional groups containing hetero atoms, involving either the formation of a carbon-to-carbon bond between two carbon atoms not directly linked already or the disconnection of two directly linked carbon atoms
    • C07B37/04—Substitution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B53/00—Asymmetric syntheses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C17/00—Preparation of halogenated hydrocarbons
    • C07C17/093—Preparation of halogenated hydrocarbons by replacement by halogens
    • C07C17/10—Preparation of halogenated hydrocarbons by replacement by halogens of hydrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/43—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C211/44—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to only one six-membered aromatic ring
    • C07C211/45—Monoamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C22/00—Cyclic compounds containing halogen atoms bound to an acyclic carbon atom
    • C07C22/02—Cyclic compounds containing halogen atoms bound to an acyclic carbon atom having unsaturation in the rings
    • C07C22/04—Cyclic compounds containing halogen atoms bound to an acyclic carbon atom having unsaturation in the rings containing six-membered aromatic rings
    • C07C22/08—Cyclic compounds containing halogen atoms bound to an acyclic carbon atom having unsaturation in the rings containing six-membered aromatic rings containing fluorine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C25/00—Compounds containing at least one halogen atom bound to a six-membered aromatic ring
    • C07C25/24—Halogenated aromatic hydrocarbons with unsaturated side chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C253/00—Preparation of carboxylic acid nitriles
    • C07C253/30—Preparation of carboxylic acid nitriles by reactions not involving the formation of cyano groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/50—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton to carbon atoms of non-condensed six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/10—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C41/00—Preparation of ethers; Preparation of compounds having groups, groups or groups
    • C07C41/01—Preparation of ethers
    • C07C41/18—Preparation of ethers by reactions not forming ether-oxygen bonds
    • C07C41/30—Preparation of ethers by reactions not forming ether-oxygen bonds by increasing the number of carbon atoms, e.g. by oligomerisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/215—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring having unsaturation outside the six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/10—Preparation of carboxylic acid esters by reacting carboxylic acids or symmetrical anhydrides with ester groups or with a carbon-halogen bond
    • C07C67/11—Preparation of carboxylic acid esters by reacting carboxylic acids or symmetrical anhydrides with ester groups or with a carbon-halogen bond being mineral ester groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/333—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by isomerisation; by change of size of the carbon skeleton
    • C07C67/343—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
    • C07D215/06—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms having only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • C07D295/033—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/205—Radicals derived from carbonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

  • the invention relates to the technical field of preparation of ⁇ -elemene derivatives, in particular to the vinylated coupling derivatives of ⁇ -elemene and their preparation and application in the preparation of antitumor drugs.
  • Elemene is a kind of small molecule volatile oil compound, which is mainly extracted from the tuber of curcuma.
  • the elemene reported in the current literature mainly includes ⁇ -elemene, ( ⁇ )- ⁇ -elemene, ⁇ -elemene and ⁇ -elemene, wherein (-)- ⁇ -elemene is Its main active ingredient that exerts anti-tumor effect has broad-spectrum anti-tumor activity, and has certain curative effects on various cancers, such as liver cancer, breast cancer, and lung cancer.
  • a variety of preparations with elemene as the main component have achieved certain anticancer effects in clinical practice.
  • ⁇ -Elemene is one of the few new anti-tumor drugs with independent intellectual property rights in my country, and the research on its derivatives has made great progress in recent years. According to the research results of the structure-activity relationship, the double bond and its skeleton of ⁇ -threne have an important influence on the activity, and the activity of any compound that does not destroy the three double bonds is not greatly affected. However, due to the low polarity, poor water solubility and low oral bioavailability of elemene, its clinical application is limited. Therefore, it is necessary to modify the structure of elemene to obtain elemene derivatives with good water solubility, higher bioavailability for oral administration, better biological activity than elemene, and less toxic and side effects.
  • ⁇ -elemene The structural modification of ⁇ -elemene began in the 1970s and has been developed to date. There are more than 150 kinds of ⁇ -elemene derivatives that have been synthesized, involving reduction-oxidation, sulfur-containing, nitrogen-containing, esters, Crisp, alcohols, glycosides and several other categories. At present, there are very few studies on the vinylation coupling of ⁇ -elemene.
  • the first purpose of the present invention is to address the deficiencies in the prior art, to construct a series of derivatives of ⁇ -elemene vinylation coupling with ⁇ -elemene as the parent, and to provide a kind of ⁇ -elemene vinyl It is expected to develop new anti-tumor drugs by chemically coupling derivatives and studying their anti-tumor activity.
  • the present invention provides ⁇ -elemene vinylated coupling derivatives, or optical isomers, racemates, single enantiomers, possible diastereoisomers, or pharmaceutically acceptable Salt, prodrug, deuterated derivative, hydrate, solvate, the structure of the vinylated coupling derivative of ⁇ -elemene is shown in formula (I):
  • R is independently selected from any one of the following structural fragments:
  • vinylated coupling derivative of ⁇ -elemene is any one of the structures shown in compounds 1-22:
  • the second object of the present invention is to provide a preparation method of the vinylated coupling derivative of ⁇ -elemene.
  • the present invention can adopt the following synthetic route for the ⁇ -elemene vinylated coupling derivative of the structure described in the preparation formula (I):
  • the ⁇ -elemene vinylation coupling derivative of the structure shown in formula (I) of the present invention is prepared by the above method, but the conditions of the above method, such as reactant, solvent, the amount of the compound used, reaction temperature, reaction The required time and the like are not limited to the above explanation.
  • the compound of the present invention can also be conveniently prepared by combining various synthetic methods described in the specification or known in the art, and such a combination can be easily performed by those skilled in the art to which the present invention belongs.
  • each synthetic route of the present invention can adopt the prior art, as disclosed in the publication number of CN110683932A.
  • the third object of the present invention is to provide said ⁇ -elemene vinylated coupling derivatives, or optical isomers, racemates, single enantiomers, possible diastereomers Constructs, or pharmaceutically acceptable salts, prodrugs, deuterated derivatives, hydrates, and solvates thereof in the preparation of antitumor drugs.
  • the fourth object of the present invention is to provide an antineoplastic drug containing a safe and effective amount of the vinylated coupling derivative of ⁇ -elemene, or its optical isomer, racemate, single pair Enantiomers, possible diastereoisomers, or pharmaceutically acceptable salts, prodrugs, deuterated derivatives, hydrates, solvates thereof.
  • the antitumor drug may also include a pharmaceutically acceptable carrier.
  • the tumor includes colon cancer and lung cancer.
  • the compound of the present invention has the activity of inhibiting the proliferation of various tumor cell lines, the compound of the present invention and its various crystal forms, pharmaceutically acceptable inorganic or organic salts, hydrates or solvates, and the compound of the present invention containing
  • the pharmaceutical composition of the main active ingredients can be used to treat, prevent and alleviate various diseases, including various cancers.
  • the pharmaceutical composition of the present invention comprises the compound of the present invention or a pharmacologically acceptable salt thereof within a safe and effective amount range and a pharmaceutically acceptable excipient or carrier.
  • safe and effective dose refers to: the amount of the compound is sufficient to obviously improve the condition without causing severe side effects.
  • the pharmaceutical composition contains 1-2000 mg of the compound of the present invention per dose, more preferably 5-1000 mg of the compound of the present invention per dose.
  • the "one dose” is a capsule or tablet.
  • “Pharmaceutically acceptable carrier” refers to: one or more compatible solid or liquid fillers or gel substances, which are suitable for human use, and must have sufficient purity and low enough toxicity. "Compatibility” herein means that the components of the composition can be blended with the compound of the present invention and with each other without significantly reducing the efficacy of the compound.
  • Examples of pharmaceutically acceptable carrier parts include cellulose and derivatives thereof (such as sodium carboxymethylcellulose, sodium ethylcellulose, cellulose acetate, etc.), gelatin, talc, solid lubricants (such as stearic acid , magnesium stearate), calcium sulfate, vegetable oil (such as soybean oil, sesame oil, peanut oil, olive oil, etc.), polyol (such as propylene glycol, glycerin, mannitol, sorbitol, etc.), emulsifier (such as), wetting agent ( Such as sodium lauryl sulfate), coloring agents, flavoring agents, stabilizers, antioxidants, preservatives, pyrogen-free water, etc.
  • cellulose and derivatives thereof such as sodium carboxymethylcellulose, sodium ethylcellulose, cellulose acetate, etc.
  • gelatin such as talc
  • solid lubricants such as stearic acid , magnesium stearate
  • calcium sulfate such
  • the administration method of the compound or pharmaceutical composition of the present invention is not particularly limited, and representative administration methods include (but not limited to): oral, intratumoral, rectal, parenteral (intravenous, intramuscular or subcutaneous) and topical administration.
  • Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules.
  • the active compound is mixed with at least one conventional inert excipient (or carrier), such as sodium citrate or dicalcium phosphate, or with: (a) fillers or solubilizers, such as starch, Lactose, sucrose, glucose, mannitol, and silicic acid; (b) binders, such as hydroxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose, and acacia; (c) humectants, such as glycerin; (d) disintegrants, such as agar, calcium carbonate, potato starch or tapioca starch, alginic acid, certain complex silicates and sodium carbonate; (e) slow agents, such as paraffin; (f) absorption accelerators, such as quaternary Amine compounds; (g) wetting agents such as cetyl alcohol and glyceryl monostea, or
  • Solid dosage forms such as tablets, dragees, capsules, pills, and granules can be prepared with coatings and shell materials such as enteric coatings and others well known in the art. They may contain opacifying agents and the active compound or release of the compound from such compositions may be at a site within the alimentary canal in a delayed manner. Examples of usable embedding components are polymeric substances and waxy substances. The active compounds can also be in microencapsulated form, if desired, with one or more of the above-mentioned excipients.
  • Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups or tinctures.
  • Liquid dosage forms may contain, in addition to the active compound, inert diluents conventionally used in the art, such as water or other solvents, solubilizers and emulsifiers, such as ethanol, isopropanol, ethyl carbonate, ethyl acetate, propylene glycol, 1,3 butanediol, dimethylformamide and oils, especially cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil and sesame oil or mixtures of these substances, etc.
  • inert diluents conventionally used in the art, such as water or other solvents, solubilizers and emulsifiers, such as ethanol, isopropanol, ethyl carbonate, ethyl acetate, propylene glycol, 1,3 butanediol, di
  • compositions can also contain adjuvants, such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
  • adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
  • Suspensions in addition to the active compounds, may contain suspending agents, such as ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum methoxide and agar, or mixtures of these substances, and the like.
  • suspending agents such as ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum methoxide and agar, or mixtures of these substances, and the like.
  • compositions for parenteral injection may comprise physiologically acceptable sterile aqueous or anhydrous solutions, dispersions, suspensions or emulsions and sterile powders for reconstitution into sterile injectable solutions or dispersions.
  • Suitable aqueous and non-aqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols, and suitable mixtures thereof.
  • Dosage forms for topical administration of a compound of this invention include ointments, powders, patches, sprays and inhalants.
  • the active ingredient is mixed under sterile conditions with a physiologically acceptable carrier and any preservatives, buffers, or propellants which may be necessary.
  • the compounds of the present invention may be administered alone or in combination with other pharmaceutically acceptable compounds.
  • a safe and effective amount of the compound of the present invention is applied to a mammal (such as a human) in need of treatment, wherein the dosage is a pharmaceutically effective dosage when administered, for a person with a body weight of 60kg, the daily
  • the dosage is usually 1-5000 mg, preferably 5-2000 mg.
  • factors such as the route of administration and the health status of the patient should also be considered for the specific dosage, which are within the skill of skilled physicians.
  • the present invention provides ⁇ -elemene vinylated coupling derivatives with structures shown in formula (I), ⁇ -elemenes with structures shown in formula (I) Pharmaceutical compositions and hydrates of aromatic vinyl-coupled derivatives, as well as isotope derivatives, chiral isomers, variants, different salts, prodrugs and preparations of these compounds.
  • the invention also provides the preparation method and application of the vinylated coupling derivatives of ⁇ -elemene, and the activity of these compounds on the proliferation of various tumor cell lines.
  • the ⁇ -elemene C(sp 3 )-C(sp 2 ) bond-coupled derivatives in the present invention are expected to be anti-tumor drug candidates for the treatment of various cancers, such as lung cancer, liver cancer, colorectal cancer, gastric cancer, and prostate cancer , ovarian cancer, breast cancer, or glioma.
  • Embodiment 1 the preparation of compound 1
  • intermediate 1d (0.150 mmol, 1.0 equiv)
  • intermediate 1e (0.300 mmol, 2.0 equiv)
  • catalyst NiCl 2 (PPh 3 ) 2 (9.8 mg, 0.015mmol, 10mol%)
  • reducing agent Zn powder (19.6mg, 0.300mmol, 2.0equiv)
  • ligand 4,4'-di-tert-butyl-2,2'-bipyridine 4.0mg, 0.015mmol, 10mol%
  • additive MgCl 2 28.6 mg, 0.300 mmol, 2.0 equiv).
  • Embodiment 2 the preparation of compound 2
  • Embodiment 3 the preparation of compound 3
  • Embodiment 4 the preparation of compound 4
  • Embodiment 5 the preparation of compound 5
  • Embodiment 6 the preparation of compound 6
  • Embodiment 7 the preparation of compound 7
  • Embodiment 8 the preparation of compound 8
  • Embodiment 9 the preparation of compound 9
  • Embodiment 10 the preparation of compound 10
  • Embodiment 11 Tumor cell proliferation inhibition experiment
  • Biological safety cabinet (Shanghai Baiji Biotechnology Co., Ltd.), constant temperature carbon dioxide incubator (THERMO), enzyme-linked immunoassay analyzer (Spark), inverted microscope (Nikon), pipette gun set (eppendorf) and centrifuge (beckman coulter) ).
  • THERMO constant temperature carbon dioxide incubator
  • THERMO enzyme-linked immunoassay analyzer
  • spark inverted microscope
  • eppendorf pipette gun set
  • centrifuge beckman coulter
  • McCoy'S 5A Zhejiang Senrui Biotechnology Co., Ltd.
  • RPMI 1640 Zhejiang Senrui Biotechnology Co., Ltd.
  • Fatal Bovine Serum BI
  • PBS Zhejiang Senrui Biotechnology Co., Ltd.
  • Trypsin Zhejiang Senrui Biotechnology Co., Ltd. company
  • DMSO Coolaber
  • CCK-8 Coolaber
  • HCT116 Human colon cancer cells
  • A549 human lung cancer cells
  • HCT116 cells use McCoy'S 5A complete medium
  • A549 cells use RPMI 1640 complete medium.
  • Inhibition rate [(A c -A s )/(A c -A b )] ⁇ 100%
  • a s Absorbance of experimental well (medium containing cells, CCK-8, drug to be tested)
  • a c Absorbance of control wells (cell-containing medium, CCK-8, vehicle (DMSO)
  • a b Absorbance of blank wells (medium without cells and drug to be tested, CCK-8)
  • 100 ⁇ M compound acts on tumor cells for 48h.
  • Compound 4 was selected to determine the IC50 value according to the above-mentioned experimental method, and the results are shown in Table 2.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)

Abstract

一种β-榄香烯乙烯基化偶联衍生物、其制备方法及其在制备抗肿瘤药物中的应用。提供了式(I)所示结构的β-榄香烯乙烯基化偶联衍生物、含有式(I)化合物的药物组合物及水合物，以及这些化合物的同位素衍生物、手性异构体、变构体、盐、前药和制剂等。还提供了β-榄香烯乙烯基化偶联衍生物的制备方法、用途，以及这些化合物对各种肿瘤细胞株增殖抑制的活性。β-榄香烯乙烯基化偶联衍生物有望成为抗肿瘤候选药物，治疗结肠癌、肺癌。

Description

β-榄香烯乙烯基化偶联衍生物及其制备和在制备抗肿瘤药物中的应用
本申请要求于2022年02月28日提交中国专利局、申请号为CN202210185780.6、发明名称为“β-榄香烯乙烯基化偶联衍生物及其制备和在制备抗肿瘤药物中的应用”的中国专利申请的优先权，其全部内容通过引用结合在本申请中。
技术领域
本发明涉及β-榄香烯衍生物的制备技术领域，具体涉及β-榄香烯乙烯基化偶联衍生物及其制备和在制备抗肿瘤药物中的应用。
背景技术
榄香烯是一类小分子挥发油类化合物，主要从温郁金的块根中提取获得。目前文献中所报道的榄香烯主要包括α-榄香烯、(±)-β-榄香烯、γ-榄香烯和δ-榄香烯，其中(-)-β-榄香烯是其发挥抗肿瘤作用的主要活性成分，具有广谱抗肿瘤活性，对多种癌症均有一定的疗效，如肝癌、乳腺癌、肺癌等。目前，以榄香烯为主要成分的多种制剂在临床上均取得了一定的抗癌疗效。
β-榄香烯作为为数不多的拥有我国自主知识产权的抗肿瘤新药，其衍生物的研究近年来已经取得了很大的进展。从构效关系的研究结果看，β-槛香烯的双键及其骨架对活性有着重要的影响，凡是不破坏3个双键的化合物，其活性均没有受到太大影响。但是由于榄香烯极性小、水溶性差，生物口服利用度低，限制了其临床应用。因此，需要对榄香烯进行结构改造以获得水溶性好、生物口服利用度更高，生物活性优于榄香烯，且毒副作用小的榄香烯衍生物。
β-榄香烯的结构修饰工作从20世纪70年代开始，发展至今，已经合成的β-榄香烯衍生物数目已有150余种，涉及到还原氧化、含硫、含氮、酯类、酥类、醇类、糖苷等几个大类。目前关于β-榄香烯乙烯基化偶联的研究少之又少。
发明内容
本发明的第一个目的是针对现有技术的不足，以β-榄香烯为母体构建一系列β-榄香烯乙烯基化偶联的衍生物，提供一种β-榄香烯乙烯基化偶联衍生物，研究其抗肿瘤活性，有望开发出新的抗肿瘤药物。
本发明提供β-榄香烯乙烯基化偶联衍生物，或其光学异构体、消旋体、单一对映异构体、可能的非对映异构体，或其药学上可接受的盐、前药、氘代衍生物、水合物、溶剂化物，所述β-榄香烯乙烯基化偶联衍生物的结构如式(I)所示：
Figure PCTCN2022132420-appb-000001
式(I)中：
R分别独立选自以下结构片段中的任意一种：
Figure PCTCN2022132420-appb-000002
进一步地，所述β-榄香烯乙烯基化偶联衍生物为化合物1～22所示结构中的任一种：
Figure PCTCN2022132420-appb-000003
本发明的第二个目的是提供一种所述β-榄香烯乙烯基化偶联衍生物的制备方法。
本发明对于制备式(I)所述结构的β-榄香烯乙烯基化偶联衍生物，可采用以下合成路线：
Figure PCTCN2022132420-appb-000004
具体包括步骤：
(1)首先将β-榄香烯A-1进行13号烯丙位的溴取代反应得中间体A-2；
(2)然后将中间体A-2通过选择性亲核取代反应得中间体A-3；
(3)最后将中间体A-3与烯基溴化物A-4进行乙烯基化偶联，得式(I)所示结构的β-榄香烯乙烯基化偶联衍生物。
本发明式(I)所示结构的β-榄香烯乙烯基化偶联衍生物通过如上的方法制得，然而上述方法的条件，如反应物、溶剂、所用化合物的量、反应温度、反应所需时间等不限于上面的解释。本发明化合物还可以任选将在本说明书中描述的或本领域已知的各种合成方法组合起来而方便的制得，这样的组合可由本发明所属领域的技术人员容易地进行。
本发明各合成路线的步骤(1)均可采用现有技术，如公开号为CN110683932A中公开的。
本发明的第三个目的是提供了所述的β-榄香烯乙烯基化偶联衍生物，或其光学异构体、消旋体、单一对映异构体、可能的非对映异构体，或其药学上可接受的盐、前药、氘代衍生物、水合物、溶剂化物在制备抗肿瘤药物中的应用。
本发明的第四个目的是提供了一种抗肿瘤药物，含有安全有效量的所述的β-榄香烯乙烯基化偶联衍生物，或其光学异构体、消旋体、单一对映异构体、可能的非对映异构体，或其药学上可接受的盐、前药、氘代衍生物、水合物、溶剂化物。
作为优选，所述抗肿瘤药物还可以包括药学上可以接受的载体。
作为优选，所述应用和所述抗肿瘤药物中，所述肿瘤包括结肠癌、肺癌。
由于本发明化合物具有抑制各种肿瘤细胞株增殖的活性，因此，本发明化合物及其各种晶型、药学上可接受的无机或有机盐、水合物或溶剂合物，以及含有本发明化合物为主要活性成分的药物组合物可用于治疗、预防以及缓解各种疾病，包括各种癌症。
本发明的药物组合物包含安全有效量范围内的本发明化合物或其药理上可接受的盐及药理上可以接受的赋形剂或载体。其中“安全有效量”指的是：化合物的量足以明显改善病情，而不至于产生严重的副作用。通常，药物组合物含有1-2000mg本发明化合物/剂，更佳地，含有5-1000mg本发明化合物/剂。较佳地，所述的“一剂”为一个胶囊或药片。
“药学上可以接受的载体”指的是：一种或多种相容性固体或液体填料或凝胶物质，它们适合于人使用，而且必须有足够的纯度和足够低的毒性。“相容性”在此指的是组合物中各组分能和本发明的化合物以及它们之间相互掺和，而不明显降低化合物的药效。药学上可以接受的载体部分例子有纤维素及其衍生物(如羧甲基纤维素钠、乙基纤维素钠、纤维素乙酸酯等)、明胶、滑石、固体润滑剂(如硬脂酸、硬脂酸镁)、硫酸钙、植物油(如豆油、芝麻油、花生油、橄榄油等)、多元醇(如丙二醇、甘油、甘露醇、山梨醇等)、乳化剂(如)、润湿剂(如十二烷基硫酸钠)、着色剂、调味剂、稳定剂、抗氧化剂、防腐剂、无热原水等。
本发明化合物或药物组合物的施用方式没有特别限制，代表性的施用方式包括(但并不限于)：口服、瘤内、直肠、肠胃外(静脉内、肌肉内或皮下)和局部给药。
用于口服给药的固体剂型包括胶囊剂、片剂、丸剂、散剂和颗粒剂。在这些固体剂型中，活性化合物与至少一种常规惰性赋形剂(或载体)混合，如柠檬酸钠或磷酸二钙，或与下述成分混合：(a)填料或增溶剂，如淀粉、乳糖、蔗糖、葡萄糖、甘露醇和硅酸；(b)粘合剂，如羟甲基纤维素、藻酸盐、明胶、聚乙烯基吡咯烷酮、蔗糖和阿拉伯胶；(c)保湿剂，如甘油；(d)崩解剂，如琼脂、碳酸钙、马铃薯淀粉或木薯淀粉、藻酸、某些复合硅酸盐和碳酸钠；(e)缓溶剂，如石蜡；(f)吸收加速剂，如季胺化合物；(g)润湿剂，如鲸蜡醇和单硬脂酸甘油酯；(h)吸附剂，如高岭土；(i)润滑剂，如滑石、硬脂酸钙、硬脂酸镁、固体聚乙二醇、十二烷基硫酸钠或其混合物。胶囊剂、片剂和丸剂中，剂型也可包含缓冲剂。
固体剂型，如片剂、糖丸、胶囊剂、丸剂和颗粒剂可采用包衣和壳材制备，如肠衣和其它本领域公知的材料。它们可包含不透明剂，并且这种组合物中活性化合物或化合物的释放可以延迟的方式在消化道内的某一部位中释放。可采用的包埋组分的实例是聚合物质和蜡类物质。必要时，活性化合物也可与上述赋形剂中的一种或多种形成微胶囊形式。
用于口服给药的液体剂型，包括药学上可接受的乳液、溶液、悬浮液、糖浆或酊剂。除了活性化合物外，液体剂型可包含本领域中常规采用的惰性稀释剂，如水或其它溶剂，增溶剂和乳化剂，如乙醇、异丙醇、碳酸乙酯、乙酸乙酯、丙二醇、1,3-丁二醇、二甲基甲酰胺以及油，特别是棉籽油、花生油、玉米胚油、橄榄油、蓖麻油和芝麻油或这些物质的混合物等。
除了这些惰性稀释剂外，组合物也可包含助剂，如润湿剂、乳化剂和悬浮剂、甜味剂、矫味剂和香料。
除了活性化合物外，悬浮液可包含悬浮剂，如乙氧基化异十八烷醇、聚氧乙烯山梨醇和脱水山梨醇酯、微晶纤维素、甲醇铝和琼脂或这些物质的混合物等。
用于肠胃外注射的组合物可包含生理上可接受的无菌含水或无水溶 液、分散液、悬浮液或乳液和用于重新溶解成无菌的可注射溶液或分散液的无菌粉末。适宜的含水和非水载体、稀释剂、溶剂或赋形剂，包括水、乙醇、多元醇及其适宜的混合物。
用于局部给药的本发明化合物的剂型包括软膏剂、散剂、贴剂、喷射剂和吸入剂。活性成分在无菌条件下与生理上可接受的载体及任何防腐剂、缓冲剂，或必要时可能需要推进剂一起混合。
本发明化合物可以单独给药，或者与其他药学上可接受的化合物联合给药。
使用药物组合物时，是将安全有效量的本发明化合物适用于需要治疗的哺乳动物(如人)，其中施用时剂量为药学上认为的有效给药剂量，对于60kg体重的人而言，日给药剂量通常为1～5000mg，优选5～2000mg。当然，具体剂量还应考虑给药途径、病人健康状况等因素，这些都是熟练医师技能范围之内的。
本发明与现有技术相比，主要优点包括：本发明提供了式(I)所示结构的β-榄香烯乙烯基化偶联衍生物、含有式(I)所示结构的β-榄香烯乙烯基化偶联衍生物的药物组合物及水合物，以及这些化合物的同位素衍生物、手性异构体、变构体、不同的盐、前药和制剂等。本发明还提供了所述β-榄香烯乙烯基化偶联衍生物的制备方法、用途，以及这些化合物对各种肿瘤细胞株的增殖的活性。本发明中的β-榄香烯C(sp 3)-C(sp 2)键偶联衍生物有望成为抗肿瘤候选药物，治疗各种癌症，如肺癌、肝癌、结直肠癌、胃癌、前列腺癌、卵巢癌、乳腺癌或脑胶质瘤等。
具体实施方式
下面结合具体实施例，进一步阐述本发明。应理解，这些实施例仅用于说明本发明而不用于限制本发明的范围。下列实施例中未注明具体条件的操作方法，通常按照常规条件，或按照制造厂商所建议的条件。
实施例1：化合物1的制备
Figure PCTCN2022132420-appb-000005
中间体1d
(1)在0℃条件下，向化合物1a(20mmol，100mol％)的二氯甲烷(DCM，80mL)溶液中加入CBr 4(30mmol，150mol％)，然后在 氮气保护的条件下通过恒压滴液漏斗逐滴滴加PPh 3(60mmol，300mol％)的DCM(70mL)溶液。TLC监测反应进程，反应完全后减压除去约一半体积的二氯甲烷，然后加入石油醚(PE，100mL)沉淀三苯基氧磷(TPPO)。硅藻土过滤和蒸发后，将残渣溶解在PE(50mL)中，使TPPO进一步沉淀。重复多次得到粗二溴化物1b(～20mmol，100mol％)，直接用于下一步。
(2)在室温条件下，向粗二溴化物1b(～20mmol，100mol％)和NEt 3(60mmol，300mol％)的无水N,N-二甲基甲酰胺(DMF，20mL)溶液中加入亚磷酸二甲酯(60mmol，300mol％)，搅拌过夜。在减压条件下将DMF蒸除，加入水溶液(60mL)，用PE(2×100mL)萃取，合并的有机相用盐酸水溶液(1M，55mL)洗涤，然后用无水硫酸钠干燥。干燥剂经过滤除去，滤液在减压条件下浓缩，所得的粗品1c直接用于下一步。
(3)将上一步的粗产物1c(～20mmol，100mol％)溶解在异丙醇(i-PrOH，30mL)中。加入固体氢氧化钠(17mmol，85mol％)加热回流>5小时。将反应混合物冷却至室温，用正己烷(100mL)萃取，合并的有机相依次用盐酸水溶液(1M，75mL)、水溶液(2×100mL)洗涤，然后用无水硫酸钠干燥。干燥剂经过滤除去，滤液在减压条件下浓缩，所得的粗品经硅胶柱层析(乙酸乙酯/石油醚(0.5％)体系洗脱)纯化，得白色固体1d(2.65g，收率62％)。 1H NMR(500MHz,CDCl 3)δ7.25–7.21(m,2H),7.04(d,J＝14.0Hz,1H),6.87–6.83(m,2H),6.61(d,J＝13.9Hz,1H),3.81(s,3H).
化合物1
向配备有磁力搅拌器的烘箱干燥过的Schlenk管中依次加入中间体1d(0.150mmol，1.0equiv)、中间体1e(0.300mmol，2.0equiv)、催化剂NiCl 2(PPh 3) 2(9.8mg，0.015mmol，10mol％)、还原剂Zn粉(19.6mg,0.300mmol,2.0equiv)、配体4,4'-二叔丁基-2,2'-联吡啶(4.0mg，0.015mmol，10mol％)以及添加剂MgCl 2(28.6mg，0.300mmol，2.0equiv)。然后通过双排管将Schlenk管抽放气三次确保反应体系存在氮气氛围下，最后用注射器加入N,N-二甲基乙酰胺(DMA，1.0mL)溶液，并在25℃下搅拌12小时。反应完全后，无需后处理，将反应混合物直接通过硅胶柱层析(乙酸乙酯/石油醚(2％)体系洗脱)纯化，得无色油状液体1(43.3mg，收率86％)。 1H NMR(500MHz,CDCl 3)δ7.31(d,J＝8.7Hz,2H),6.85(d,J＝8.7Hz,2H),6.37(d,J＝15.8Hz,1H),6.08(dt,J＝15.7,7.1Hz,1H),5.83(dd,J＝17.4,10.9Hz,1H),4.92(dd,J＝8.1,1.2Hz,1H),4.89(s,1H),4.87(s,1H),4.83(dd,J＝5.0,1.3Hz,2H),4.61(s,1H),3.81(s,3H),2.95(d,J＝7.0Hz,2H),2.02(dd,J＝11.8,4.3Hz,2H),1.72(s,3H),1.64–1.59(m,2H),1.54–1.42(m,4H),1.02(s,3H). 13C NMR (126MHz,CDCl 3)δ158.92, 153.40,150.38,147.81,130.81,130.65,127.27,126.63,114.06,112.26,110.01,108.76,55.41,52.90,44.30,40.09,39.98,38.83,33.36,27.33,24.93,16.76. HRMS(ESI)m/z([M-H] -)calcd for C 24H 31O:335.2380.Found:335.2380.
实施例2：化合物2的制备
Figure PCTCN2022132420-appb-000006
中间体2d
参照实施例1里面中间体1d的合成步骤，得无色油状液体2d(881mg，收率21％)。 1H NMR (500MHz,CDCl 3)δ8.07(d,J＝2.5Hz,1H),7.55(dd,J＝8.6,2.5Hz,1H),7.03(d,J＝14.0Hz,1H),6.71(d,J＝8.7Hz,1H),6.66(d,J＝14.0Hz,1H),3.94(s,3H).
化合物2
参照实施例1里面化合物1的合成步骤，得无色油状液体2(36.9mg，收率73％)。 1H NMR (500MHz,CDCl 3)δ8.08(t,J＝5.5Hz,1H),7.64(dd,J＝8.6,2.4Hz,1H),6.69(d,J＝8.6Hz,1H),6.34(d,J＝15.9Hz,1H),6.10(dt,J＝15.8,7.0Hz,1H),5.81(dd,J＝17.3,11.0Hz,1H),4.99–4.75(m,5H),4.59(s,1H),3.93(s,3H),2.95(d,J＝6.9Hz,2H),1.99(ddd,J＝15.9,11.2,5.0Hz,2H),1.71(s,3H),1.65–1.56(m,3H),1.50–1.41(m,3H),1.01(s,3H). 13C NMR (126MHz,CDCl 3)δ163.43,153.06,150.32,147.77,145.08,135.54,128.25,127.52,126.97,112.29,110.93,110.07,109.01,53.61,52.90,44.41,40.02(d,J＝11.8Hz),38.83,33.37,29.84,27.32,24.93,16.76. HRMS(ESI)m/z([M+H] +)calcd for C 23H 32NO:338.2478.Found:338.2475.
实施例3：化合物3的制备
Figure PCTCN2022132420-appb-000007
化合物3
参照实施例1里面化合物1的合成步骤，得无色油状液体3(39.7mg，收率80％)。 1H NMR (500MHz,CDCl 3)δ7.75(d,J＝8.3Hz,2H),7.43(d,J＝8.3Hz,2H),6.36(ddd,J＝30.6,15.8,11.4Hz,2H),5.81(dd,J＝17.3,11.0Hz,1H),4.94–4.87(m,3H),4.82(d,J＝5.9Hz,2H),4.59(s,1H),2.99(d,J＝6.8Hz,2H),2.01(dt,J＝18.0,10.4Hz,2H),1.71(s,3H),1.64–1.56(m,3H),1.52–1.42(m,3H),1.01(s,3H). 13C NMR (126MHz,CDCl 3)δ169.12,152.70,150.29,147.77,141.53,131.61,130.50,127.86,126.29,112.31,110.10,109.32,100.12,52.89,44.48,40.01(d,J＝9.9Hz),38.82,33.36,29.84,27.30,24.93,16.77. HRMS(ESI)m/z([M+H] +)calcd for C 24H 30N:332.2373.Found:332.2378.
实施例4：化合物4的制备
Figure PCTCN2022132420-appb-000008
化合物4
参照实施例1里面化合物1的合成步骤，得无色油状液体4(43.1mg，收率77％)。 1H NMR (500MHz,CDCl 3)δ8.54(s,1H),8.10(s,1H),7.61(d,J＝8.5Hz,2H),7.49(d,J＝8.6Hz,2H),6.44(d,J＝15.8Hz,1H),6.29(dt,J＝15.8,7.0Hz,1H),5.82(dd,J＝17.3,11.0Hz,1H),4.97–4.87(m,3H),4.83(d,J＝1.4Hz,2H),4.60(s,1H),2.99(d,J＝6.9Hz,2H),2.06–1.97(m,2H),1.71(s,3H),1.64–1.58(m,3H),1.52–1.42(m,3H),1.01(s,3H). 13C NMR (126MHz,CDCl 3)152.81,152.68,150.29,147.77,140.84,137.95,135.73,130.55,130.06,127.38,120.29,112.32,110.11,109.26,52.90,44.49,40.06, 39.98,38.78,33.37,27.32,24.94,16.77. HRMS(ESI)m/z([M+H] +)calcd for C 25H 32N 3:374.2591.Found:374.2590.
实施例5：化合物5的制备
Figure PCTCN2022132420-appb-000009
中间体5g
参照实施例1里面中间体1d的合成步骤，得白色固体5d，然后在冰浴条件下，向化合物5d(358mg，1.58mmol)和化合物5f(288.4mg，1.5mmol)的无水DCM(10mL)溶液中，依次加入DMAP(37mg，0.3mmol)、DCC(464mg，2.25mmol)，搅拌过夜。在减压条件下将DCM蒸除，向残余物中加入水溶液(40mL)，然后用乙酸乙酯(3×20mL)萃取。合并的有机相用饱和食盐水(2×20mL)洗涤，然后用无水硫酸钠干燥。干燥剂经过滤除去，滤液在减压条件下浓缩，所得的粗品经硅胶柱层析(乙酸乙酯/石油醚(0.5％)体系洗脱)纯化，得白色固体5g(581mg，收率97％)。 1H NMR (500MHz,CDCl 3)δ7.93(d,J＝8.4Hz,2H),7.32(d,J＝8.3Hz,2H),7.18(d,J＝8.0Hz,2H),7.15–7.07(m,3H),6.90(d,J＝14.0Hz,1H),4.42–4.33(m,2H),3.26–3.18(m,1H),2.45(d,J＝7.2Hz,2H),1.84(dt,J＝13.5,6.8Hz,1H),1.38(d,J＝7.0Hz,3H),0.89(d,J＝6.6Hz,6H).
化合物5
参照实施例1里面化合物1的合成步骤，得无色油状液体5(67.6mg，收率86％)。 1H NMR (500MHz,CDCl 3)δ7.91(d,J＝7.9Hz,2H),7.38(d,J＝8.0Hz,2H),7.19(d,J＝7.7Hz,2H),7.10(d,J＝7.7Hz,2H),6.49–6.30(m,2H),5.82(d,J＝6.4Hz,1H),5.01(s,1H),4.93–4.92(m,1H),4.89(s,1H),4.83(s,2H),4.58–4.57(m,1H),4.42–4.31(m,2H),3.21(dd,J＝13.9, 7.0Hz,1H),2.99(d,J＝6.7Hz,2H),2.45(d,J＝7.1Hz,2H),2.09(s,3H),2.01(d,J＝6.8Hz,2H),1.85(dt,J＝13.3,6.7Hz,1H),1.60(s,2H),1.47(s,4H),1.38(d,J＝6.8Hz,3H),0.99(s,3H),0.90(d,J＝6.6Hz,6H). 13C NMR (126MHz,CDCl 3)δ194.56,170.79,166.38,152.57,150.20,150.07,148.49,147.40,142.14,140.45,140.09,131.70,130.66,129.96,129.30,127.11,125.95,112.38,111.02,110.13,109.28,70.02,66.20,52.77,45.13,44.42,41.93,39.90,38.79,33.13,30.29,27.13,24.90,22.48(d,J＝3.1Hz),21.08,18.13,16.69. HRMS(ESI)m/z([M+H] +)calcd for C 37H 49O 2:525.3727.Found:525.3722.
实施例6：化合物6的制备
Figure PCTCN2022132420-appb-000010
中间体6g
参照实施例5里面中间体5g的合成步骤，得无色油状液体6g(267mg，收率82％)。 1H NMR (500MHz,CDCl 3)δ7.98(d,J＝8.3Hz,2H),7.34(d,J＝8.3Hz,2H),7.13(d,J＝14.0Hz,1H),6.91(d,J＝14.0Hz,1H),5.09(t,J＝7.1Hz,1H),4.40–4.29(m,2H),1.99(dd,J＝22.5,7.6Hz,2H),1.80(dt,J＝12.5,6.3Hz,1H),1.66(s,3H),1.59(s,3H),1.34–1.28(m,2H),1.24(dd,J＝15.0,7.7Hz,2H),0.96(d,J＝6.6Hz,3H).
化合物6
参照实施例1里面化合物1的合成步骤，得无色油状液体6(63.7mg，收率87％)。 1H NMR (500MHz,CDCl 3)δ7.97(d,J＝7.9Hz,2H),7.41(d,J＝8.0Hz,2H),6.50–6.29(m,2H),5.82(dd,J＝17.4,10.8Hz,1H),5.10(dd,J＝6.9,5.9Hz,1H),4.92(s,1H),4.91(s,1H),4.89(d,J＝2.6Hz,1H),4.82(d,J＝5.1Hz,2H),4.60(s,1H),4.46–4.27(m,2H),2.99(d,J＝6.8Hz,2H),2.07–1.97(m,4H),1.92(d,J＝10.1Hz,1H),1.86–1.79(m,1H),1.75(d,J＝9.2Hz,1H),1.71(s,3H),1.68(s,3H),1.61(s,3H),1.56(d,J＝8.1Hz,1H), 1.51–1.44(m,3H),1.31(dd,J＝17.7,7.5Hz,4H),1.01(s,3H),0.97(d,J＝6.5Hz,3H). 13C NMR (126MHz,CDCl 3)δ166.64,152.66,150.27,147.72,142.14,131.72,131.48,130.72,130.00,129.01 125.99,124.71,112.30,110.08,109.31,63.53,52.87,44.47,40.00(d,J＝10.8Hz),38.84,37.13,35.66,35.06,33.35,29.72,27.30,25.84,25.54,24.93,19.65,17.80,16.75. HRMS(ESI)m/z([M+H] +)calcd for C 34H 49O 2:489.3727.Found:489.3730.
实施例7：化合物7的制备
Figure PCTCN2022132420-appb-000011
中间体7g
参照实施例5里面中间体5g的合成步骤，得无色油状液体7g(281mg，收率89％)。 1H NMR (500MHz,CDCl 3)δ8.00(d,J＝8.2Hz,2H),7.35(d,J＝8.3Hz,2H),7.13(d,J＝14.0Hz,1H),6.91(d,J＝14.0Hz,1H),5.84(s,1H),4.73–4.70(m,3H),2.17(d,J＝3.6Hz,1H),1.93–1.89(m,2H),1.74(s,3H),1.58–1.49(m,2H),1.30(d,J＝9.8Hz,2H).
化合物7
参照实施例1里面化合物1的合成步骤，得无色油状液体7(59.5mg，收率82％)。 1H NMR (500MHz,CDCl 3)δ7.97(d,J＝8.3Hz,2H),7.40(d,J＝8.3Hz,2H),6.38(dt,J＝15.8,12.4Hz,2H),5.82–5.80(m,2H),5.00(s,1H),4.91(s,1H),4.88(d,J＝2.1Hz,1H),4.81(s,2H),4.71(dd,J＝8.9,5.0Hz,4H),4.57(s,1H),2.98(d,J＝6.7Hz,2H),2.17(d,J＝5.1Hz,3H),2.08(s,3H),2.01(s,2H),1.90(d,J＝10.0Hz,3H),1.70–1.69(m,3H),1.59(s,2H),1.46(d,J＝3.4Hz,4H),1.29(s,1H),1.00–0.99(m,3H). 13C NMR (126MHz,CDCl 3)δ194.56,170.79,154.90,152.57,150.06,148.48,147.40,132.89,131.73,130.66,130.02,125.96,125.59,112.36,111.01,110.12,108.90,68.78,66.20,55.80,52.76,48.46,45.71,44.42,41.92,40.95,39.89,38.79,36.51,35.00,33.12,30.56. HRMS(ESI)m/z([M+H] +)calcd for  C 34H 45O 2:485.3414.Found:485.3409.
实施例8：化合物8的制备
Figure PCTCN2022132420-appb-000012
化合物8
参照实施例1里面化合物1的合成步骤，得无色油状液体8(50.1mg，收率75％)。 1H NMR (500MHz,CDCl 3)δ8.01(d,J＝7.7Hz,1H),7.59(d,J＝3.6Hz,1H),7.32(d,J＝7.5Hz,1H),7.24(t,J＝3.9Hz,1H),6.72(d,J＝3.3Hz,2H),6.32(dt,J＝15.7,7.1Hz,1H),5.80(dd,J＝17.4,10.9Hz,1H),4.93–4.77(m,5H),4.58(s,1H),3.02(d,J＝7.0Hz,2H),2.00(dd,J＝12.0,3.9Hz,2H),1.70(s,3H),1.65(s,12H),1.46(ddd,J＝9.0,7.8,2.6Hz,3H),1.00(s,3H). 13C NMR (126MHz,CDCl 3)δ153.17,150.37,147.82,135.65,134.23,130.42(d,J＝8.5Hz),128.63,125.92,124.48,119.37,115.42,114.66,113.93,112.29,110.04,109.06,105.62,83.83,52.92,44.45,40.05(d,J＝12.6Hz),39.20,33.41,29.85,28.34,27.36,24.94,16.78. HRMS(ESI)m/z([M-H] -)calcd for C 30H 38NO 2:444.2908.Found:444.2908.
实施例9：化合物9的制备
Figure PCTCN2022132420-appb-000013
中间体9g
参照实施例5里面中间体5g的合成步骤，得无色油状液体9g(416mg，收率69％)。 1H NMR (500MHz,CDCl 3)δ7.99(d,J＝8.4Hz,2H),7.34(d,J＝8.3Hz,2H),7.13(d,J＝14.1Hz,1H),6.90(d,J＝14.0Hz,1H),5.45(t,J＝7.0Hz,1H),4.83(d,J＝7.0Hz,2H),2.04(d,J＝5.1Hz,2H),1.75(s,3H),1.51(dd,J＝13.3,6.7Hz,1H),1.39–1.11(m,20H),0.88–0.81(m,12H).
化合物9
参照实施例1里面化合物1的合成步骤，得无色油状液体9(73.6mg，收率78％)。 1H NMR (500MHz,CDCl 3)δ7.98(d,J＝8.4Hz,2H),7.40(d,J＝8.4Hz,2H),6.54–6.26(m,2H),5.82(dd,J＝17.3,11.0Hz,1H),5.46(dd,J＝7.0,6.0Hz,1H),4.93–4.89(m,2H),4.83(dd,J＝5.9,4.0Hz,3H),4.60(s,1H),3.20(dt,J＝13.3,5.0Hz,1H),2.99(d,J＝6.8Hz,2H),2.07–1.98(m,5H),1.95–1.89(m,2H),1.75(s,3H),1.71(s,3H),1.63–1.57(m,5H),1.48(ddd,J＝13.1,9.9,5.1Hz,8H),1.16–1.12(m,5H),1.09–1.05(m,5H),1.01(s,3H),0.86(d,J＝5.5Hz,12H). 13C NMR (126MHz,CDCl 3)δ166.66,152.68,150.29,147.74,142.87,142.13,131.69,130.74,130.07,129.03,125.98,118.37,112.31,110.08,109.32,61.98,55.89,52.88,44.47,40.05,39.79,39.52,38.85,37.57,37.51,37.44,36.77,35.07,33.36,32.87(d,J＝15.3Hz),29.85,28.12,27.30,25.60,25.19,24.94,24.61,22.82(d,J＝11.7Hz),19.88(d,J＝3.7Hz),16.69(d,J＝18.4Hz),14.27. HRMS(ESI)m/z([M+H] +)calcd for C 44H 69O 2:629.5292.Found:629.5291.
实施例10：化合物10的制备
Figure PCTCN2022132420-appb-000014
中间体10g
参照实施例5里面中间体5g的合成步骤，得白色固体10g(1.07g，收率91％)。 1H NMR (500MHz,CDCl 3)δ7.97(dd,J＝8.5,1.6Hz,2H),7.39–7.34(m,2H),7.34–7.30(m,2H),7.30–7.27(m,2H),7.20(dd,J＝8.1,6.8Hz,2H),7.16–7.10(m,4H),6.91(d,J＝14.1Hz,1H),6.82–6.76(m,2H),6.62–6.56(m,2H),4.57(dd,J＝5.5,3.9Hz,2H),4.16(dd,J＝5.6,3.9Hz,2H),3.41(t,J＝7.4Hz,2H),2.92(t,J＝7.5Hz,2H).
化合物10
参照实施例1里面化合物1的合成步骤，得无色油状液体10(86.4mg，收率81％)。 1H NMR (500MHz,CDCl 3)δ7.96(d,J＝8.2Hz,2H),7.42–7.36(m,4H),7.31(d,J＝6.2Hz,3H),7.23–7.19(m,2H),7.16(d,J＝7.2Hz,3H),6.82(d,J＝8.7Hz,2H),6.61(d,J＝8.7Hz,2H),6.51–6.31(m,2H),5.86–5.80(m,1H),5.11(d,J＝13.8Hz,1H),4.92(s,1H),4.91(s,1H),4.84(d,J＝6.9Hz,2H),4.61(s,1H),4.59–4.56(m,2H),4.20–4.14(m,2H),3.43(t,J＝7.4Hz,2H),3.00(d,J＝8.7Hz,2H),2.95–2.91(m,2H),2.05–2.00(m,2H),1.73(s,3H),1.62(dd,J＝7.5,3.3Hz,2H),1.51–1.45(m,4H),1.03(s,3H). 13C NMR (126MHz,CDCl 3)δ166.44,156.86,152.58,150.24,148.88,147.68,142.94,142.41,141.75,141.03,135.41(d,J＝5.3Hz),131.93,131.86,130.62,130.16,129.63,129.49,128.46,128.34,127.07,126.73,125.98,113.72,113.13,112.29,110.07,109.33,79.52,65.88,63.33,52.83,44.43,42.93,41.65,39.96(d,J＝9.6Hz),38.75(d,J＝14.8Hz),33.31,29.81,27.26,24.92. HRMS(ESI)m/z([M+Na] +)calcd for C 48H 51ClNaO 3:733.3419.Found:733.3482.
实施例11：肿瘤细胞增殖抑制实验
体外抗肿瘤活性评价
1.实验设备与试剂
1.1仪器
生物安全柜(上海百基生物科技有限公司)、恒温二氧化碳培养箱(THERMO)、酶联免疫分析仪(Spark)、倒置显微镜(Nikon)、移液枪一套(eppendorf)和离心机(beckman coulter)。
1.2试剂
McCoy’S 5A(浙江森瑞生物科技有限公司)、RPMI 1640(浙江森瑞生物科技有限公司)、Fatal Bovine Serum(BI)、PBS(浙江森瑞生物科技有限公司)、Trypsin(浙江森瑞生物科技有限公司)、DMSO(Coolaber)和CCK-8(Coolaber)。
1.3细胞株
人结肠癌细胞(HCT116)、人肺癌细胞(A549)。
2.实验方法
1)取对数生长期的受试细胞，经胰酶消化、计数后，以5×10 4/mL的浓度接种于96孔培养板中，每孔100μL(每孔5×10 3个细胞)，于37℃，5％CO 2培养箱中培养24h；
2)用McCoy’S 5A或RPMI 1640完全培养基稀释待测药物至不同浓度。实验组更换含不同浓度被测样品的培养液，对照组更换含等体积溶剂(DMSO)的培养液，每组设立3个平行孔，于37℃，5％CO 2培养箱中继续培养48h；
其中，HCT116细胞使用McCoy’S 5A完全培养基，A549细胞使用RPMI 1640完全培养基。
3)每孔加入CCK-8溶液10μL，于37℃继续培养1-4h，酶标仪在490nm处测定每个孔的吸光度值(OD值)；
4)用以下公式计算存活率和抑制率
细胞存活率＝[(A s-A b)/(A c-A b)]×100％
抑制率＝[(A c-A s)/(A c-A b)]×100％
应用GraphPad Prism 7.0软件,使用非线性回归模型绘制S型剂量-存活率曲线并计算IC 50值。
A s：实验孔(含有细胞的培养基、CCK-8、待测药物)的吸光度
A c：对照孔(含有细胞的培养基、CCK-8、溶媒(DMSO)的吸光度
A b：空白孔(不含细胞和待测药物的培养基、CCK-8)的吸光度
3.实验结果
按上述实验方法测定了目标化合物以及阳性对照药β-榄香烯对两种肿瘤细胞的增殖抑制作用，结果如表1所示。
表1 目标化合物对肿瘤细胞抑制率的影响
Figure PCTCN2022132420-appb-000015
100μM化合物作用于肿瘤细胞48h。
结果显示，化合物4的抗肿瘤细胞增殖作用明显强于阳性对照β-榄香烯。
选取化合物4按上述实验方法测定IC 50值，结果如表2所示。
表2 目标化合物对肿瘤细胞的半数抑制浓度
Figure PCTCN2022132420-appb-000016
不同浓度的化合物作用于肿瘤细胞48h。
结果显示，化合物4表现出明显强于阳性对照β-榄香烯的抑制细胞增殖的活性。
此外应理解，在阅读了本发明的上述描述内容之后，本领域技术人员可以对本发明作各种改动或修改，这些等价形式同样落于本申请所附权利要求书所限定的范围。

Claims (15)

  1. β-榄香烯乙烯基化偶联衍生物，或其光学异构体、消旋体、单一对映异构体、非对映异构体，或其药学上可接受的盐、前药、氘代衍生物、水合物、溶剂化物，其特征在于，所述β-榄香烯衍生物的结构如式(I)所示：
    Figure PCTCN2022132420-appb-100001
    式(I)中R为芳基、杂芳基、烷基。
  2. 根据权利要求1所述的β-榄香烯乙烯基化偶联衍生物，或其光学异构体、消旋体、单一对映异构体、非对映异构体，或其药学上可接受的盐、前药、氘代衍生物、水合物、溶剂化物，其特征在于，所述β-榄香烯衍生物式(I)所示结构中的R分别独立选自以下结构片段中的任意一种：
    Figure PCTCN2022132420-appb-100002
  3. 根据权利要求1所述的β-榄香烯乙烯基化偶联衍生物，或其光学异构体、消旋体、单一对映异构体、非对映异构体，或其药学上可接受的盐、前药、氘代衍生物、水合物、溶剂化物，其特征在于，所述β-榄香烯乙烯 基化偶联衍生物为化合物1～22所示结构中的任一种：
    Figure PCTCN2022132420-appb-100003
  4. 权利要求1-3任一项所述的β-榄香烯乙烯基化偶联衍生物的制备方法，其特征在于，采用如下合成路线：
    Figure PCTCN2022132420-appb-100004
    具体包括步骤：
    (1)首先将β-榄香烯A-1进行烯丙位单溴取代反应得中间体A-2；
    (2)然后将中间体A-2通过选择性亲核取代反应得中间体A-3；
    (3)最后将中间体A-3与烯溴A-4进行乙烯基化偶联，得式(I)所示结构的β-榄香烯乙烯基化偶联衍生物；
    其中R分别独立选自以下结构片段中的任意一种：
    Figure PCTCN2022132420-appb-100005
  5. 根据权利要求1-3任一项所述的β-榄香烯乙烯基化偶联衍生物，或其光学异构体、消旋体、单一对映异构体、非对映异构体，或其药学上可接受的盐、前药、氘代衍生物、水合物、溶剂化物在制备抗肿瘤药物中的应用。
  6. 根据权利要求5所述的应用，其特征在于，所述肿瘤包括结肠癌、肺癌、肝癌、胃癌、前列腺癌、卵巢癌、乳腺癌或脑胶质瘤。
  7. 根据权利要求5所述的应用，其特征在于，权利要求1～3任一项所述的β-榄香烯乙烯基化偶联衍生物，或其光学异构体、消旋体、单一对映异构体、可能的非对映异构体，或其药学上可接受的盐、前药、氘代衍生物、水合物、溶剂化物的施用方式包括：口服、瘤内、直肠、肠胃外和局部给药。
  8. 根据权利要求7所述的应用，其特征在于，用于口服给药的固体剂型包括胶囊剂、片剂、丸剂、散剂和颗粒剂；
    所述固体剂型中，权利要求1～3任一项所述的β-榄香烯乙烯基化偶联衍生物，或其光学异构体、消旋体、单一对映异构体、可能的非对映异构体，或其药学上可接受的盐、前药、氘代衍生物、水合物、溶剂化物与至少一种惰性赋形剂或载体混合，所述惰性赋形剂或载体包括柠檬酸钠、磷酸二钙，或与填料或增溶剂，粘合剂，保湿剂，崩解剂，缓溶剂，吸收加速剂，润湿剂，吸附剂，润滑剂混合；所述填料或增溶剂为淀粉、乳糖、蔗糖、葡萄糖、甘露醇和硅酸；所述粘合剂为羟甲基纤维素、藻酸盐、明胶、聚乙烯基吡咯烷酮、蔗糖和阿拉伯胶；所述保湿剂为甘油；所述崩解剂为琼脂、碳酸钙、马铃薯淀粉或木薯淀粉、藻酸、某些复合硅酸盐和碳酸钠；所述缓溶剂为石蜡；吸收加速剂为季胺化合物；所述润湿剂为鲸蜡醇和单硬脂酸甘油酯；所述吸附剂为高岭土；所述润滑剂为滑石、硬脂酸钙、硬脂酸镁、固体聚乙二醇、十二烷基硫酸钠或其混合物。
  9. 根据权利要求5所述的应用，其特征在于，对于60kg体重的人而言，日给药剂量为1～5000mg。
  10. 一种抗肿瘤药物，其特征在于，含有安全有效量的权利要求1～3任一项所述的β-榄香烯乙烯基化偶联衍生物，或其光学异构体、消旋体、单一对映异构体、可能的非对映异构体，或其药学上可接受的盐、前药、氘代衍生物、水合物、溶剂化物。
  11. 根据权利要求10所述的一种抗肿瘤药物，其特征在于，所述抗肿瘤药物还包括药学上可以接受的赋形剂或载体。
  12. 根据权利要求10或11所述的一种抗肿瘤药物，其特征在于，所述肿瘤包括结肠癌、肺癌。
  13. 根据权利要求10所述的一种抗肿瘤药物，其特征在于，所述抗肿瘤药物含有1-2000mg/剂的权利要求1～3任一项所述的β-榄香烯乙烯基化偶联衍生物，或其光学异构体、消旋体、单一对映异构体、可能的非对映异构体，或其药学上可接受的盐、前药、氘代衍生物、水合物、溶剂化物；一剂为一个胶囊或药片。
  14. 根据权利要求10所述的一种抗肿瘤药物，其特征在于，所述药学上可以接受的载体包括纤维素及其衍生物、明胶、滑石、固体润滑剂、硫 酸钙、植物油、多元醇、乳化剂、润湿剂、着色剂、调味剂、稳定剂、抗氧化剂、防腐剂、无热原水。
  15. 根据权利要求10所述的一种抗肿瘤药物，其特征在于，所述片剂、糖丸、胶囊剂、丸剂和颗粒剂采用包衣和壳材制备。
PCT/CN2022/132420 2022-02-28 2022-11-17 β-榄香烯乙烯基化偶联衍生物及其制备和在制备抗肿瘤药物中的应用 WO2023160035A1 (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP22924566.7A EP4276087A1 (en) 2022-02-28 2022-11-17 Beta-elemene vinylation coupled derivative, and preparation thereof and use thereof in preparation of antitumor drug
JP2023550584A JP2024510390A (ja) 2022-02-28 2022-11-17 β－エレメンビニル化カップリング誘導体、及びその調製、並びに抗腫瘍薬の調製における使用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202210185780.6A CN114524716B (zh) 2022-02-28 2022-02-28 β-榄香烯乙烯基化偶联衍生物及其制备和在制备抗肿瘤药物中的应用
CN202210185780.6 2022-02-28

Publications (1)

Publication Number Publication Date
WO2023160035A1 true WO2023160035A1 (zh) 2023-08-31

Family

ID=81623834

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2022/132420 WO2023160035A1 (zh) 2022-02-28 2022-11-17 β-榄香烯乙烯基化偶联衍生物及其制备和在制备抗肿瘤药物中的应用

Country Status (4)

Country Link
EP (1) EP4276087A1 (zh)
JP (1) JP2024510390A (zh)
CN (1) CN114524716B (zh)
WO (1) WO2023160035A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114524716B (zh) * 2022-02-28 2023-04-25 杭州师范大学 β-榄香烯乙烯基化偶联衍生物及其制备和在制备抗肿瘤药物中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1850779A (zh) * 2006-05-10 2006-10-25 沈阳药科大学 β－榄香烯含氮衍生物及其制备方法和用途
EP3034610A1 (en) * 2013-08-13 2016-06-22 The Kitasato Institute Novel terpenoid compound and method for producing same
CN110683932A (zh) 2019-09-29 2020-01-14 杭州师范大学 β-榄香烯卤代物及其制备方法
CN114524716A (zh) * 2022-02-28 2022-05-24 杭州师范大学 β-榄香烯乙烯基化偶联衍生物及其制备和在制备抗肿瘤药物中的应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1850779A (zh) * 2006-05-10 2006-10-25 沈阳药科大学 β－榄香烯含氮衍生物及其制备方法和用途
EP3034610A1 (en) * 2013-08-13 2016-06-22 The Kitasato Institute Novel terpenoid compound and method for producing same
CN110683932A (zh) 2019-09-29 2020-01-14 杭州师范大学 β-榄香烯卤代物及其制备方法
CN114524716A (zh) * 2022-02-28 2022-05-24 杭州师范大学 β-榄香烯乙烯基化偶联衍生物及其制备和在制备抗肿瘤药物中的应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BAI, RENREN ET AL.: "Rational Design, Synthesis and Biological Evaluation of Novel Derivatives Based on In Vivo Metabolism of Natural Product β-elemene", LETTERS IN DRUG DESIGN & DISCOVERY, vol. 15, no. 8, 31 August 2018 (2018-08-31), pages 905 - 912, XP009548589, ISSN: 1875-628X *
YE YANG, QI XIANG, XU BING, LIN YING, XIANG HUAN, ZOU LIANG, YE XIANG-YANG, XIE TIAN: "Nickel-catalyzed cross-electrophile allylation of vinyl bromides and the modification of anti-tumour natural medicine β-elemene", CHEMICAL SCIENCE, ROYAL SOCIETY OF CHEMISTRY, UNITED KINGDOM, vol. 13, no. 23, 15 June 2022 (2022-06-15), United Kingdom , pages 6959 - 6966, XP093088893, ISSN: 2041-6520, DOI: 10.1039/D2SC02054H *

Also Published As

Publication number Publication date
JP2024510390A (ja) 2024-03-07
CN114524716A (zh) 2022-05-24
CN114524716B (zh) 2023-04-25
EP4276087A1 (en) 2023-11-15

Similar Documents

Publication Publication Date Title
CN106749494B (zh) 具有肿瘤耐药逆转活性的α-常春藤皂苷元衍生物及其制备方法和用途
CN113698401B (zh) β-榄香烯大环衍生物及其制备方法和应用
WO2012175044A1 (zh) 用于肿瘤治疗的水溶性铂配合物及其制备方法
WO2023160035A1 (zh) β-榄香烯乙烯基化偶联衍生物及其制备和在制备抗肿瘤药物中的应用
WO2023160039A1 (zh) 具有HDACi药效团的β-榄香烯衍生物及其制备方法和应用
WO2015096640A1 (zh) 含噻唑基雷帕霉素类衍生物及其应用
WO2023280182A1 (zh) 作为kat6抑制剂的化合物
KR101068259B1 (ko) 헤테로사이클기에 고리－축합된 신규 베툴린산 유도체
WO2023160011A1 (zh) 一种含N-OH键的β-榄香烯衍生物及其制备方法和应用
CN114605407B (zh) 一种吲哚喹啉酮类化合物及其合成方法和应用
CN110627615B (zh) β-榄香烯氧化物及制备方法和用途
CN106608892B (zh) 含氟水溶性铂配合物及制备方法及用途
CN114057824A (zh) 雷公藤红素衍生物及其制备方法与用途
CN110551080B (zh) 紫杉烷类化合物及其药物组合物和用途
CN116375601B (zh) 一种抗黑色素瘤化合物及其制备方法和应用
CN106608898B (zh) 含脱氧葡萄糖水溶性铂配合物及制备方法及用途
SK13762003A3 (sk) Deriváty 5-tio-beta-D-xylopyranozidov, spôsob ich prípravy, farmaceutické kompozície tieto deriváty obsahujúce a ich terapeutické použitie
CN112279863A (zh) Hsp90抑制剂与喜树碱衍生物的偶联物及其制备方法与应用
CN116120327A (zh) β-榄香烯13,14-位对称的双取代衍生物及其制备方法和应用
FI80440C (fi) Analogifoerfarande foer framstaellning av terapeutiskt anvaendbara afidkolanderivat.
CN111763236B (zh) 一类沙蟾毒精氨基甲酸酯衍生物及其应用
WO2023284872A1 (zh) 一种dpp4抑制活性化合物的多晶型及其制备方法
EP1758904B1 (en) Flavopereirine derivatives for cancer therapy
CN116730890A (zh) 一种光学活性三氟甲磺酰基过氧化物衍生物及其制备方法
WO2022237852A1 (zh) 一类烷基酚类化合物及其制备方法

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2022924566

Country of ref document: EP

Effective date: 20230808

WWE Wipo information: entry into national phase

Ref document number: 2023550584

Country of ref document: JP